Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.9800+0.0800 (+2.05%)
At close: 04:00PM EDT
4.1500 +0.17 (+4.27%)
After hours: 04:35PM EDT
Advertisement
Sign in to post a message.
  • D
    Davebiotech
    Reminds me of CLDX.
  • a
    ageninrussia
    Loncar:

    This environment certainly raises the ante for management teams and investors. Example: $MGNX essentially says 'we don't currently have the budget to run our prostate cancer trial, but we're pretty sure we can figure it out'.
  • L
    Lets_be_friend
    Can any longs give a statement on why one should have a position in this stock with current evaluation? Looking at current SP Am thinking of making some position hence asking.
  • Y
    Yahoo Finance Insights
    MacroGenics reached a 52 Week low at 7.41
  • B
    Bombastic
    (ZYNE) $1.37 ...BIG Cannabis Play trading at Cash with Blockbuster Pipeline near data readout =1000% OPP
    https://assets.wallstreet-online.de/_media/8763/board/20220328161124-screenshot-2022-03-28-at-16-10-45-powerpoint-pres.png

    ##
  • D
    Davebiotech
    This company is an utter flop. Although Ive seen co' go from a few bux to 20' and the flop again to a few bux and then get bought for 30's. Can it happen here? God only knows.
    Bullish
  • T
    Trillion
    The worse scam of all. JPM CREATED this scam. They rattled people in believing this will be a great opportunity while they pump it and dumped millions of shares in the high 30s and 40s and 60s, then they themselves short it to thus level thus leaving many bagholders behind...
    Corruption at its max, and the SEC, sleeping as always. Allowing the scam to continue just about everyone among gigantic financial institutions..
    When it gets to the boom, they pump this again
  • b
    betasplen
    This one is so tempting to short. No phase 3 results in yet and so much excitement. I will just take 250 shares for now and if there is a follow through tomorrow am, I shall take another swipe at it.
  • D
    Dwight Schrute
    Can someone please tell me how this company is worth a billion dollars based on their revenue?
  • C
    CP
    This is a weird reaction. Their primary asset does not overperform the standard treatment and the price goes up. Can anybody explain this to me? I am puzzled.
  • T
    Thomas
    Those who think its going past 30. Please show me why! Earnings. Revenue anything solid the show me why the book value of the stock is more than $2 please. Besides an analyst I'd like to see some hard numbers. I dont see it.
    Bearish
  • p
    peter
    Literally every molecule in their listed pipeline is active in the clinic (7/7) (1 still not assessed). That's an amazing unmatched record as far as I am aware.
  • H
    Henry
    The phase 2/3 result is very positive. Why still drop like a stone?
    21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A

    78% of patients had tumor shrinkage at first scan

    Median duration of response was 10.3 months as of data cutoff

    Margetuximab plus retifanlimab was well tolerated with Grade 3 treatment-related adverse events (TRAEs) in 19% of patients; no Grade 4 TRAEs or treatment-related deaths

    Findings suggest this chemotherapy-free combination, if validated and approved, may be a potential option for first-line HER2+ patients
    Bullish
  • B
    Barbara Ann
    05/06/2020: Credit Suisse analyst Evan Seigerman maintains rating on Macrogenix (MGNX), Lowers Price Target to $13.
    Bearish
  • J
    JeffreyT
    I think the stock may be reacting to the new Trastuzumab/drug conjugates. Astra Zeneca payed a bundle to Daiichi to share rights to one such conjugate. I'm not buying that this therapy will be first line, however, for most patients. That said, the shares are under pressure and it doesn't seem like it's time to buy (again) just yet. There are only so many mega players, so a buyout seems less likely, as well.
  • B
    Biotech
  • S
    Smallcap Lover
    great news on positive phase 3 results targeting breast cancer, congrats to the longs and GLTA https://smallcapreporter.wordpress.com/2019/02/06/3-healthcare-stocks-setting-the-pace-on-wednesday/
    The global medical technology industry’s market size is currently about USD $400 billion and is forecast grow to USD $495 billion over the next three years, according to a PwC report. The term “med…
    The global medical technology industry’s market size is currently about USD $400 billion and is forecast grow to USD $495 billion over the next three years, according to a PwC report. The term “med…
    smallcapreporter.wordpress.com
  • p
    peter
    I just entered here. Couldn't pass up the opportunity. T-cell engagers are problematic and dosing needs to be worked out, but they are also quite active. Same problem happened with AFMD and their lead T-cell engager (AFM11). Quite an active drug but put on hold for a death at higher dose in the p1 trial. This will likely be lifted and allowed to proceed at lower dosing, but no green light yet. AFMD does have some advantage, as its NK engagers don't seem to have the narrow therapeutic index for dosing. However, MGNX has other products that seem quite promising. I think both companies are big potential winners. Today's dive is a good entry point here IMO.
  • m
    ming
    50$ target by end of next year! MGNX is an acquisition target eventually, could be bought at 100$/share. We should see 30$ yesterday, market reaction was wrong, but today is a better day!
    Bullish
  • H
    Harvey
    This looks like $VSTM all over again. High expectations and speculators driving the price up pre-data release then a big crash when data underwhelms. Wednesday will be the day
Advertisement
Advertisement